References

Reference articles

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Full text  Abstract

2. World Health Organization. Tracking SARS-CoV-2 variants. 2022 [internet publication].Full text

3. UK Health Security Agency. Investigation of SARS-CoV-2 variants: technical briefing documents on novel SARS-CoV-2 variants. 2021 [internet publication].Full text

4. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2021 [internet publication].Full text

5. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021 Jun 15;373:n1412.Full text  Abstract

6. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1507-17.Full text  Abstract

7. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1518-28.Full text  Abstract

8. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-45.Full text  Abstract

9. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern Med. 2021 Dec 22 [Epub ahead of print].Full text  Abstract

10. World Health Organization. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. January 7 2022 [internet publication].Full text

11. Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA. 2021 Dec 30 [Epub ahead of print].Full text  Abstract

12. Wolter N, Jassat W, Walaza S, et al; medRxiv. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa [preprint]. 2021 [internet publication].Full text

13. Jassat W, Karim SA, Mudara C, et al; SSRN. Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicron-dominant fourth wave [preprint]. 2021 [internet publication].Full text

14. Sheikh A, Kerr S, Woolhouse M, et al. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland [preprint]. 2021 [internet publication].Full text

15. Kozlov M. Omicron’s feeble attack on the lungs could make it less dangerous. 2021 [internet publication].Full text

16. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern [preprint]. 2021 [internet publication].Full text

17. Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2021 Dec 29 [Epub ahead of print].Full text  Abstract

18. Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. 2021 [internet publication].Full text

19. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Full text  Abstract

20. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Full text  Abstract

21. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Full text  Abstract

22. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143-56.Full text  Abstract

23. World Health Organization. COVID-19 disease in children and adolescents: scientific brief, 29 September 2021. 2021 [internet publication].Full text

24. Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12-17 years with laboratory-confirmed COVID-19: COVID-NET, 14 states, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):851-7.Full text  Abstract

25. Somekh I, Stein M, Karakis I, et al. Characteristics of SARS-CoV-2 infections in Israeli children during the circulation of different SARS-CoV-2 variants. JAMA Netw Open. 2021 Sep 1;4(9):e2124343.Full text  Abstract

26. Zhu Y, Bloxham CJ, Hulme KD, et al. A meta-analysis on the role of children in severe acute respiratory syndrome coronavirus 2 in household transmission clusters. Clin Infect Dis. 2021 Jun 15;72(12):e1146-53.Full text  Abstract

27. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Full text  Abstract

28. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020 Aug 27;370:m3249.Full text  Abstract

29. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135,794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr. 2021 Feb 1;175(2):176-84.Full text  Abstract

30. Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide. PLoS One. 2021 Jan 29;16(1):e0246326.Full text  Abstract

31. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Full text  Abstract

32. Allotey J, Stallings E, Bonet M, et al. Update to living systematic review on covid-19 in pregnancy. BMJ. 2021 Mar 10;372:n615.Full text  Abstract

33. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Full text  Abstract

34. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020 Jun 8;369:m2107.Full text  Abstract

35. Centers for Disease Control and Prevention. Data on COVID-19 during pregnancy: severity of maternal illness. 2022 [internet publication].Full text

36. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Full text  Abstract

37. World Health Organization. Prevention, identification and management of health worker infection in the context of COVID-19. 2020 [internet publication].Full text

38. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Full text  Abstract

39. Chou R, Dana T, Buckley DI, et al. Update alert 10: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2021 Nov 16;M21-4294.Full text  Abstract

40. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Full text  Abstract

41. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Full text  Abstract

42. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Full text  Abstract

43. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Full text  Abstract

44. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Full text  Abstract

45. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Full text  Abstract

46. Roberts DL, Rossman JS, Jarić I. Dating first cases of COVID-19. PLoS Pathog. 2021 Jun;17(6):e1009620.Full text  Abstract

47. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. 2020 [internet publication].Full text

48. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021 Jan;174(1):69-79.Full text  Abstract

49. World Health Organization. Mask use in the context of COVID-19: interim guidance. 2020 [internet publication].Full text

50. Birgand G, Peiffer-Smadja N, Fournier S, et al. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA Netw Open. 2020 Dec 1;3(12):e2033232.Full text  Abstract

51. Razani N, Malekinejad M, Rutherford GW. Clarification regarding "Outdoor transmission of SARS-CoV-2 and other respiratory viruses: a systematic review". J Infect Dis. 2021 Sep 1;224(5):925-6.Full text  Abstract

52. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021 Jun;34(3):155-70.Full text  Abstract

53. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Res. 2021 Mar 24;10:233.Full text  Abstract

54. Trypsteen W, Van Cleemput J, Snippenberg WV, et al. On the whereabouts of SARS-CoV-2 in the human body: a systematic review. PLoS Pathog. 2020 Oct;16(10):e1009037.Full text  Abstract

55. World Health Organization. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief. 2021 [internet publication].Full text

56. Zhu F, Zozaya C, Zhou Q, et al. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2021 Sep;106(5):514-21.Full text  Abstract

57. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Full text  Abstract

58. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. 2020 [internet publication].Full text

59. Read JM, Green CA, Harrison EM, et al. Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet. 2021 Sep 18;398(10305):1037-8.Full text  Abstract

60. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Full text  Abstract

61. Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang Province, China. JAMA Intern Med. 2021 Oct 1;181(10):1343-50.Full text  Abstract

62. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission: a living systematic review. Clin Microbiol Infect. 2021 Apr;27(4):511-9.Full text  Abstract

63. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Full text  Abstract

64. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Full text  Abstract

65. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Full text  Abstract

66. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2021 Jan;93(1):518-21.Full text  Abstract

67. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Full text  Abstract

68. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Full text  Abstract

69. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Full text  Abstract

70. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Full text  Abstract

71. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Full text  Abstract

72. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Full text  Abstract

73. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Full text  Abstract

74. Chen X, Huang Z, Wang J, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021 Dec 7;11(12):e049752.Full text  Abstract

75. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for patients with COVID-19: Nashville, Tennessee. Clin Infect Dis. 2021 May 4;72(9):1645-8.Full text  Abstract

76. Althouse BM, Wenger EA, Miller JC, et al. Superspreading events in the transmission dynamics of SARS-CoV-2: opportunities for interventions and control. PLoS Biol. 2020 Nov 12;18(11):e3000897.Full text  Abstract

77. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Full text  Abstract

78. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Full text  Abstract

79. Xu W, Li X, Dong Y, et al. SARS-CoV-2 transmission in schools: an updated living systematic review (version 2; November 2020). J Glob Health. 2021 Jun 10;11:10004.Full text  Abstract

80. Karki SJ, Joachim A, Heinsohn T, et al. Risk of infection and contribution to transmission of SARS-CoV-2 in school staff: a systematic review. BMJ Open. 2021 Nov 3;11(11):e052690.Full text  Abstract

81. Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet. 2021 Oct 2;398(10307):1217-29.Full text  Abstract

82. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Full text  Abstract

83. World Health Organization. Living guidance for clinical management of COVID-19. 2021 [internet publication].Full text

84. Xin H, Wong JY, Murphy C, et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Infect Dis. 2021 Dec 16;73(12):2344-52.Full text  Abstract

85. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Full text  Abstract

86. Ahammed T, Anjum A, Rahman MM, et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: a systematic review and meta-analysis. Health Sci Rep. 2021 Jun;4(2):e274.Full text  Abstract

87. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2021 [internet publication].Full text

88. Hussein M, Toraih E, Elshazli R, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Ann Surg. 2021 Mar 1;273(3):416-23. Abstract

89. Pung R, Mak TM, Kucharski AJ, et al; CMMID COVID-19 working group. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases. Lancet. 2021 Sep 4;398(10303):837-8.Full text  Abstract

90. Tian T, Huo X. Secondary attack rates of COVID-19 in diverse contact settings, a meta-analysis. J Infect Dev Ctries. 2020 Dec 31;14(12):1361-7.Full text  Abstract

91. Thompson HA, Mousa A, Dighe A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021 Aug 2;73(3):e754-64.Full text  Abstract

92. Madewell ZJ, Yang Y, Longini IM Jr, et al. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2122240.Full text  Abstract

93. Viner R, Waddington C, Mytton O, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect. 2021 Dec 22 [Epub ahead of print].Full text  Abstract

94. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 May;21(5):629-36.Full text  Abstract

95. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-22.Full text  Abstract

96. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 Dec 24;383(26):2586-8.Full text  Abstract

97. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Full text  Abstract

98. Menezes RG, Rizwan T, Saad Ali S, et al. Postmortem findings in COVID-19 fatalities: a systematic review of current evidence. Leg Med (Tokyo). 2021 Dec 7;54:102001.Full text  Abstract

99. Lancet Respiratory Medicine. COVID-19: pathophysiology of acute disease. 2021 [internet publication].Full text

100. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021;16(4):e0250708.Full text  Abstract

101. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Full text  Abstract

102. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Full text  Abstract

103. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Abstract

104. Piplani S, Singh PK, Winkler DA, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021 Jun 24;11(1):13063.Full text  Abstract

105. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-6.Full text  Abstract

106. Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines. Vaccines (Basel). 2021 Jan 11;9(1):36.Full text  Abstract

107. Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021 Aug;21(8):1070.Full text  Abstract

108. Milross L, Majo J, Cooper N, et al. Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. Lancet Respir Med. 2021 Dec 3;10(1):95-106.Full text  Abstract

109. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021 Jun;9(6):622-42.Full text  Abstract

110. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Full text  Abstract

111. Downes DJ, Cross AR, Hua P, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021 Nov;53(11):1606-15.Full text  Abstract

112. Saengsiwaritt W, Jittikoon J, Chaikledkaew U, et al. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta-analysis. Rev Med Virol. 2022 Jan 8;:e2323.Full text  Abstract

113. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 [internet publication].Full text

114. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): contact tracing. 2022 [internet publication].Full text

115. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021 Jan 11;11(1):e044640.Full text  Abstract

116. Romero Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021 Dec;6(12):e006434.Full text  Abstract

117. Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group. 2021 [internet publication].Full text

118. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Full text  Abstract

119. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Full text  Abstract

120. Damayanthi HDWT, Prabani KIP. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: a systematic review. Arch Gerontol Geriatr. 2021 Mar 31;95:104411.Full text  Abstract

121. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Full text  Abstract

122. Baldassarri M, Picchiotti N, Fava F, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021 Feb 26;65:103246.Full text  Abstract

123. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100630.Full text  Abstract

124. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021 Mar;174(3):362-73.Full text  Abstract

125. Khanijahani A, Iezadi S, Gholipour K, et al. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021 Nov 24;20(1):248.Full text  Abstract

126. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-24.Full text  Abstract

127. Saatci D, Ranger TA, Garriga C, et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr. 2021 Sep 1;175(9):928-38.Full text  Abstract

128. Acosta AM, Garg S, Pham H, et al. Racial and ethnic disparities in rates of COVID-19–associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021. JAMA Netw Open. 2021 Oct 1;4(10):e2130479.Full text  Abstract

129. Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147.Full text  Abstract

130. Agyemang C, Richters A, Jolani S, et al. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. BMJ Glob Health. 2021 Nov;6(11):e007433.Full text  Abstract

131. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2021 Sep 1;175(9):928-38.Full text  Abstract

132. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Full text  Abstract

133. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. 2021 [internet publication].Full text

134. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Full text  Abstract

135. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Full text  Abstract

136. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021 Apr 1;181(4):439-48.Full text  Abstract

137. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Full text  Abstract

138. Norris T, Razieh C, Zaccardi F, et al. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart. 2021 Dec 15 [Epub ahead of print].Full text  Abstract

139. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020 – March 2021. Prev Chronic Dis. 2021 Jul 1;18:E66.Full text  Abstract

140. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Full text  Abstract

141. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Full text  Abstract

142. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021 Feb 9;12(1):e03647-20.Full text  Abstract

143. Zuin M, Rigatelli G, Bilato C, et al. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021 Sep 27;13(10):1938.Full text  Abstract

144. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. BMC Public Health. 2021 Aug 4;21(1):1505.Full text  Abstract

145. World Obesity Federation. COVID-19 and obesity: the 2021 atlas. 2021 [internet publication].Full text

146. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.Full text  Abstract

147. Kompaniyets L, Goodman AB, Belay B, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death: United States, March – December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.Full text  Abstract

148. Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021 Aug 11;21(1):1533.Full text  Abstract

149. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis. Am J Emerg Med. 2021 Aug;46:382-91.Full text  Abstract

150. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients. J Interv Card Electrophysiol. 2021 Nov;62(2):231-8.Full text  Abstract

151. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: a systematic review and meta-analysis. Cardiol J. 2021 Dec 13 [Epub ahead of print]. Abstract

152. Liang C, Zhang W, Li S, et al. Coronary heart disease and COVID-19: a meta-analysis. Med Clin (Engl Ed). 2021 Jun 11;156(11):547-54.Full text  Abstract

153. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-80.Full text  Abstract

154. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021 Mar 11;(3):CD013879.Full text  Abstract

155. Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021 Dec;44(12):2790-811.Full text  Abstract

156. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Full text  Abstract

157. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Full text  Abstract

158. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Full text  Abstract

159. Papadopoulos VP, Koutroulos MV, Zikoudi DG, et al. Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis. Diabetol Int. 2021 Mar 23;1-15.Full text  Abstract

160. Prattichizzo F, de Candia P, Nicolucci A, et al. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20:e3476.Full text  Abstract

161. Heidarpour M, Abhari AP, Sadeghpour N, et al. Prediabetes and COVID-19 severity, an underestimated risk factor: a systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Oct 9;15(6):102307.Full text  Abstract

162. Yang W, Sun X, Zhang J, et al. The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. Diabetes Res Clin Pract. 2021 Jul 22;178:108977.Full text  Abstract

163. Yang Y, Cai Z, Zhang J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: a meta-analysis. PLoS One. 2021;16(5):e0251916.Full text  Abstract

164. Kahkoska AR, Abrahamsen TJ, Alexander GC, et al. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 2021 Jun 16;44(7):1564-72.Full text  Abstract

165. Patoulias D, Doumas M. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies. Endocrinol Metab (Seoul). 2021 Aug;36(4):904-8.Full text  Abstract

166. Kan C, Zhang Y, Han F, et al. Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021 Sep 16;12:708494.Full text  Abstract

167. Han T, Ma S, Sun C, et al. The association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res. 2021 Aug 9 [Epub ahead of print].Full text  Abstract

168. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Full text  Abstract

169. Yin Y, Rohli KE, Shen P, et al. The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2021 Sep 6;15(6):899-909.Full text  Abstract

170. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Full text  Abstract

171. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Full text

172. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Mar;33:100789.Full text  Abstract

173. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):699-711.Full text  Abstract

174. Otunla A, Rees K, Dennison P, et al. Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses. BMJ Evid Based Med. 2021 Dec 21 [Epub ahead of print].Full text  Abstract

175. World Health Organization. Asthma and COVID-19: scientific brief, 19 April 2021. 2021 [internet publication].Full text

176. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med. 2021 Apr 1;82:47-53.Full text  Abstract

177. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 Jan;8(1):e000845.Full text  Abstract

178. Mathew HR, Choi MY, Parkins MD, et al. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173.Full text  Abstract

179. Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021 Oct;93(10):5682-6.Full text  Abstract

180. Aggarwal AN, Agarwal R, Dhooria S, et al. Active pulmonary tuberculosis and coronavirus disease 2019: a systematic review and meta-analysis. PLoS One. 2021;16(10):e0259006.Full text  Abstract

181. Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: a meta-analysis. Int Immunopharmacol. 2021 Sep 9;100:108145.Full text  Abstract

182. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Sep;55(9):2412-8.Full text  Abstract

183. Lin YC, Lai TS, Lin SL, et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.Full text  Abstract

184. Chung EY, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2021 Dec;78(6):804-15.Full text  Abstract

185. Nopsopon T, Kittrakulrat J, Takkavatakarn K, et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156.Full text  Abstract

186. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Full text  Abstract

187. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Full text  Abstract

188. Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021 Oct;8(1):e000739.Full text  Abstract

189. Tao Z, Li Y, Cheng B, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):830-5.Full text  Abstract

190. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Full text  Abstract

191. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Full text  Abstract

192. Gajbhiye RK, Sawant MS, Kuppusamy P, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2021 Oct;155(1):48-56.Full text  Abstract

193. Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcome in COVID-19 patients: a systemic review and meta-analysis. Eur J Integr Med. 2021 Feb 18:101313.Full text  Abstract

194. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health. 2021 Aug 16;21(1):1554.Full text  Abstract

195. Salah HM, Sharma T, Mehta J. Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms. Cureus. 2020 Oct 7;12(10):e10837.Full text  Abstract

196. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Full text  Abstract

197. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication].Full text

198. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Full text  Abstract

199. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102.Full text  Abstract

200. Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e180-91.Full text  Abstract

201. Nadkarni AR, Vijayakumaran SC, Gupta S, et al. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol. 2021 Aug;7:1286-305.Full text  Abstract

202. Kaur H, Thakur JS, Paika R, et al. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-49.Full text  Abstract

203. OnCovid Study Group; Pinato DJ, Patel M, Scotti L, et al. Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid registry. JAMA Oncol. 2021 Nov 24 [Epub ahead of print].Full text  Abstract

204. Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2021 Oct 28 [Epub ahead of print].Full text  Abstract

205. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Full text  Abstract

206. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021 Oct;22(10):1416-26.Full text  Abstract

207. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, et al. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2020 Jan 21;10:608282.Full text  Abstract

208. Schlage S, Lehrnbecher T, Berner R, et al. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr. 2022 Jan 10 [Epub ahead of print].Full text  Abstract

209. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Full text  Abstract

210. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2021 Jan;268(1):240-7.Full text  Abstract

211. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Nov 1;78(11):1208-17.Full text  Abstract

212. Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1079-91.Full text  Abstract

213. Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2020 Nov 14;35(1):100588.Full text  Abstract

214. Ao G, Wang Y, Qi X, et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando). 2021 May 21;35(3):100628.Full text  Abstract

215. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021 Apr;174(4):572-6.Full text  Abstract

216. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374:n1592.Full text  Abstract

217. Bosworth ML, Ayoubkhani D, Nafilyan V, et al. Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study. Lancet Public Health. 2021 Nov;6(11):e817-25.Full text  Abstract

218. Lee JX, Chieng WK, Lau SCD, et al. COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med (Lausanne). 2021 Oct 13;8:757510.Full text  Abstract

219. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 Oct;174(10):1483-7.Full text  Abstract

220. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Full text  Abstract

221. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Full text  Abstract

222. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Full text  Abstract

223. World Health Organization. Hypertension and COVID-19. 2021 [internet publication].Full text

224. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Full text  Abstract

225. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Full text  Abstract

226. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-55.Full text  Abstract

227. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Full text  Abstract

228. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Full text  Abstract

229. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9.Full text  Abstract

230. Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Nov 19;93:104299.Full text  Abstract

231. Saragih ID, Saragih IS, Batubara SO, et al. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021 Sep-Oct;42(5):1230-9.Full text  Abstract

232. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Full text

233. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Aug;17(8):1297-306.Full text  Abstract

234. Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021 Oct;3(10):e724-36.Full text  Abstract

235. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Full text  Abstract

236. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2021 Apr;87(4):2111-20.Full text  Abstract

237. Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021 Feb;51(2):199-205.Full text  Abstract

238. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan;8(1):e24-32.Full text  Abstract

239. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.Full text  Abstract

240. Chanda D, Minchella PA, Kampamba D, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection: Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):807-10.Full text  Abstract

241. Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021 Nov;8(11):e690-700.Full text  Abstract

242. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021 Dec;9(4):1160-85.Full text  Abstract

243. Lee KW, Yap SF, Ngeow YF, et al. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021 Mar 30;18(7):3554.Full text  Abstract

244. Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021 Mar 15;35(4):F1-10.Full text  Abstract

245. Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021 Mar 18;11(1):6283.Full text  Abstract

246. Hariyanto TI, Rosalind J, Christian K, et al. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021 Apr 15;22(1):1220.Full text  Abstract

247. World Health Organization. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. 2021 [internet publication].Full text

248. Wang H, Jonas KJ. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc. 2021 Nov;24(11):e25841.Full text  Abstract

249. Baillargeon J, Polychronopoulou E, Kuo YF, et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021 May 1;72(5):578-81.Full text  Abstract

250. Allen B, El Shahawy O, Rogers ES, et al. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2021 Sep 22;43(3):462-5.Full text  Abstract

251. Qeadan F, Tingey B, Bern R, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data. EClinicalMedicine. 2021 Jun 4:100938.Full text  Abstract

252. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021 Jun 1;4(6):e2111182.Full text  Abstract

253. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin d (vitamin d) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021 Mar 29;8:660420.Full text  Abstract

254. Crafa A, Cannarella R, Condorelli RA, et al. Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul;37:100967.Full text  Abstract

255. Szarpak L, Rafique Z, Gasecka A, et al. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19. Cardiol J. 2021;28(5):647-54.Full text  Abstract

256. Shah K, V P V, Pandya A, et al. Low vitamin D levels and prognosis in a COVID-19 pediatric population: a systematic review. QJM. 2021 Nov 5;114(7):447-53.Full text  Abstract

257. Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients. 2021 Oct 14;13(10):3596.Full text  Abstract

258. Ebrahimzadeh A, Mohseni S, Narimani B, et al. Association between vitamin D status and risk of covid-19 in-hospital mortality: a systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2021 Dec 9:1-11. Abstract

259. Dissanayake HA, de Silva NL, Sumanatilleke M, et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab. 2021 Dec 11 [Epub ahead of print].Full text  Abstract

260. Bassatne A, Basbous M, Chakhtoura M, et al. The link between COVID-19 and vitamin D (VIVID): a systematic review and meta-analysis. Metabolism. 2021 Mar 24:154753.Full text  Abstract

261. Grove A, Osokogu O, Al-Khudairy L, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737.Full text  Abstract

262. Chen J, Mei K, Xie L, et al. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J. 2021 Oct 31;20(1):89.Full text  Abstract

263. Toubasi AA, AbuAnzeh RB, Khraisat BR, et al. Proton pump inhibitors: current use and the risk of coronavirus infectious disease 2019 development and its related mortality - meta-analysis. Arch Med Res. 021 Aug;52(6):656-9.Full text  Abstract

264. Pranata R, Huang I, Lawrensia S, et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep. 2021 Dec;73(6):1642-9.Full text  Abstract

265. Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021 Jan;289(1):125-8.Full text  Abstract

266. Yan C, Chen Y, Sun C, et al. Will proton pump inhibitors lead to a higher risk of COVID-19 infection and progression to severe disease? A meta-analysis. Jpn J Infect Dis. 2021 May 31 [Epub ahead of print].Full text  Abstract

267. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2021 Nov 24 [Epub ahead of print].Full text  Abstract

268. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2021 Sep;70(9):1806-8.Full text  Abstract

269. Israelsen SB, Ernst MT, Lundh A, et al. Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1845-54.Full text  Abstract

270. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13 [Epub ahead of print].Full text  Abstract

271. Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639.Full text  Abstract

272. Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2022 Jan;4(1):e33-41.Full text  Abstract

273. Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2021 Oct 27 [Epub ahead of print].Full text  Abstract

274. Alrashed F, Battat R, Abdullah I, et al. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Oct;8(1):e000774.Full text  Abstract

275. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 Jul;69(7):1213-7.Full text  Abstract

276. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Full text  Abstract

277. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-32.Full text  Abstract

278. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021 Mar;9(2):159-76.Full text  Abstract

279. Sperger J, Shah KS, Lu M, et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open. 2021 Nov 12;11(11):e049740.Full text  Abstract

280. Sakthiswary R, Chuah HY, Chiang KS, et al. COVID-19 in systemic lupus erythematosus: a pooled analysis and systematic review of case reports and series. Lupus. 2021 Oct;30(12):1946-54.Full text  Abstract

281. Rutherford MA, Scott J, Karabayas M, et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: a binational, registry-based cohort study. Arthritis Rheumatol. 2021 Sep;73(9):1713-9.Full text  Abstract

282. Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-64.Full text  Abstract

283. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Full text  Abstract

284. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Jun 1;78(6):699-708.Full text  Abstract

285. Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4):e1001.Full text  Abstract

286. Giovanella L, Ruggeri RM, Ovčariček PP, et al. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021 Mar 11:1-8.Full text  Abstract

287. Malik J, Zaidi SMJ, Waqar AU, et al. Association of hypothyroidism with acute COVID-19: a systematic review. Expert Rev Endocrinol Metab. 2021 Sep;16(5):251-7. Abstract

288. Damara FA, Muchamad GR, Ikhsani R, et al. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021 Oct 22;15(6):102312.Full text  Abstract

289. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021 Jun;87:155-61.Full text  Abstract

290. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, et al. Factors associated with COVID-19 in people with Parkinson's disease: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3467-77.Full text  Abstract

291. Khoshnood RJ, Zali A, Tafreshinejad A, et al. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2021 Nov 17 [Epub ahead of print].Full text  Abstract

292. Jaiswal V, Alquraish D, Sarfraz Z, et al. The influence of coronavirus disease-2019 (COVID-19) on Parkinson's disease: an updated systematic review. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211039709.Full text  Abstract

293. Sallis R, Young DR, Tartof SY, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021 Oct;55(19):1099-105.Full text  Abstract

294. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Full text  Abstract

295. Zuin M, Rigatelli G, Bilato C, et al. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021 Oct 7;114(6):390-7.Full text  Abstract

296. Liu Y, Pan Y, Yin Y, et al. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021 Jul 27;18(1):157.Full text  Abstract

297. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. J Clin Exp Hepatol. 2021 Feb 8 [Epub ahead of print].Full text  Abstract

298. Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021 Aug 3 [Epub ahead of print].Full text  Abstract

299. Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One. 2021 Jul 15;16(7):e0254635.Full text  Abstract

300. Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: a registry-based cohort study. PLoS Med. 2021 Oct;18(10):e1003820.Full text  Abstract

301. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Full text  Abstract

302. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Full text  Abstract

303. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Full text  Abstract

304. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020 Dec 8:100785.Full text  Abstract

305. Gutiérrez-Valencia M, Leache L, Librero J, et al. ABO blood group and risk of COVID-19 infection and complications: a systematic review and meta-analysis. Transfusion. 2021 Nov 12 [Epub ahead of print].Full text  Abstract

306. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12;19(4):317-26.Full text  Abstract

307. Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021 Mar 9;5(5):1305-9.Full text  Abstract

308. Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: a systematic review. PLoS One. 2021 Jun 23;16(6):e0253293.Full text  Abstract

309. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Full text  Abstract

310. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Full text  Abstract

311. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-78.Full text  Abstract

312. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.Full text  Abstract

313. Zheng HL, Guo ZL, Wang ML, et al. Effects of climate variables on the transmission of COVID-19: a systematic review of 62 ecological studies. Environ Sci Pollut Res Int. 2021 Oct;28(39):54299-316.Full text  Abstract

314. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Full text

315. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: a systematic review. Environ Res. 2020 Aug 24;191:110129.Full text  Abstract

316. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Full text  Abstract

317. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Full text  Abstract

318. Bowyer RCE, Varsavsky T, Thompson EJ, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2021 Jul;76(7):723-5.Full text  Abstract

319. World Health Organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. 2021 [internet publication].Full text

320. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance. 2021 [internet publication].Full text

321. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™). 2021 [internet publication].Full text

322. World Health Organization. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. 2021 [internet publication].Full text

323. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm, 7 May 2021. 2021 [internet publication].Full text

324. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance. 2021 [internet publication].Full text

325. World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19. 2021 [internet publication].Full text

326. World Health Organization. Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19. 2021 [internet publication].Full text

327. UK Health Security Agency. Consent: the green book, chapter 2. 2021 [internet publication].Full text

328. Amit S, Beni SA, Biber A, et al. Post-vaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. 2021 Feb 1;27(4).Full text  Abstract

329. Zhang M, Liang Y, Yu D, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 Delta variant. Int J Biol Sci. 2022;18(2):889-900.Full text  Abstract

330. Kampf G. The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Reg Health Eur. 2021 Dec;11:100272.Full text  Abstract

331. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022 Jan;22(1):43-55.Full text  Abstract

332. Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2021 Dec 28 [Epub ahead of print].Full text  Abstract

333. Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021 Dec;9(12):1439-49.Full text  Abstract

334. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021 Nov 16;326(19):1930-9.Full text  Abstract

335. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021 Nov;21(11):1485-6.Full text  Abstract

336. Butt AA, Yan P, Shaikh OS, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. EClinicalMedicine. 2021 Aug 28;40:101117.Full text  Abstract

337. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings: Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-62.Full text  Abstract

338. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. 2021 [internet publication].Full text

339. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021 Oct 29 [Epub ahead of print].Full text  Abstract

340. World Health Organization. Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. 2021 [internet publication].Full text

341. Department of Health and Social Care. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. 2021 [internet publication].Full text

342. UK Health Security Agency. COVID-19: the green book, chapter 14a. 2022 [internet publication].Full text

343. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. 2022 [internet publication].Full text

344. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of an additional COVID-19 vaccine dose in immunocompromised people. 2021 [internet publication].Full text

345. European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. 2021 [internet publication].Full text

346. World Health Organization. Interim statement on booster doses for COVID-19 vaccination. 2021 [internet publication].Full text

347. World Health Organization. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). 2022 [internet publication].Full text

348. Department of Health and Social Care. JCVI advice on the UK vaccine response to the Omicron variant. 2021 [internet publication].Full text

349. UK Health Security Agency. JCVI issues new vaccination advice for children and young people. 2021 [internet publication].Full text

350. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of COVID-19 vaccine booster doses. 2021 [internet publication].Full text

351. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393-400.Full text  Abstract

352. Falsey AR, Frenck RW Jr, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021 Oct 21;385(17):1627-9.Full text  Abstract

353. Hause AM, Baggs J, Gee J, et al. Safety monitoring of an additional dose of COVID-19 vaccine: United States, August 12 – September 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-84.Full text  Abstract

354. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Dec 4;398(10316):2093-100.Full text  Abstract

355. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258-76.Full text  Abstract

356. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021 Dec 23;385(26):2413-20.Full text  Abstract

357. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021 Dec 23;385(26):2421-30.Full text  Abstract

358. Croda J, Ranzani OT. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. Lancet Infect Dis. 2021 Dec 7 [Epub ahead of print].Full text  Abstract

359. World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. 2021 [internet publication].Full text

360. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121-30.Full text  Abstract

361. Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021 Sep 9;385(11):1049-51.Full text  Abstract

362. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021 Jul 29;21(9):1212-3.Full text  Abstract

363. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021 Nov;9(11):1255-65.Full text  Abstract

364. Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021 Oct 18:100249.Full text  Abstract

365. Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021 May 29;397(10289):2043-6.Full text  Abstract

366. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4;398(10303):856-69.Full text  Abstract

367. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021 Dec 6;399(10319):36-49.Full text  Abstract

368. European Medicines Agency. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19. 2021 [internet publication].Full text

369. World Health Organization. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. 2021 [internet publication].Full text

370. UK Health Security Agency. JCVI issues updated advice on COVID-19 booster vaccination. 2021 [internet publication].Full text

371. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2022 [internet publication].Full text

372. Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Dec 18;398(10318):2277-87.Full text  Abstract

373. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults. Circulation. 2021 Dec 6 [Epub ahead of print].Full text  Abstract

374. Gundry SR. Abstract 10712: MRNA COVID vaccines dramatically increase endothelial inflammatory markers and ACS risk as measured by the PULS cardiac test: a warning. Circulation. 2021 Nov 16;144 (Suppl 1):A10712.Full text

375. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021 Dec 14 [Epub ahead of print].Full text  Abstract

376. Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine: weekly summary of Yellow Card reporting. 2022 [internet publication].Full text

377. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices: United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-82.Full text  Abstract

378. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021 Dec 2;385(23):2132-9.Full text  Abstract

379. Sharff KA, Dancoes DM, Longueil JL, et al; medRxiv. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: a comparison of completeness and timeliness of two methods [preprint]. 2021 [internet publication].Full text

380. Matta A, Kunadharaju R, Osman M, et al. Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review. Cureus. 2021 Nov;13(11):e19240.Full text  Abstract

381. Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021 Dec 1;6(12):1446-50.Full text  Abstract

382. UK Health Security Agency. Myocarditis and pericarditis after COVID-19 vaccination: guidance for healthcare professionals. 2021 [internet publication].Full text

383. Shafiq A, Salameh MA, Laswi I, et al. Neurological immune related adverse events post-COVID-19 vaccination: a systematic review. J Clin Pharmacol. 2021 Dec 18 [Epub ahead of print].Full text  Abstract

384. Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA. 2021 Oct 26;326(16):1606-13.Full text  Abstract

385. Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 2021 Dec 1;6(12):1451-60.Full text  Abstract

386. Hafeez MU, Ikram M, Shafiq Z, et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211048815.Full text  Abstract

387. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices: United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-99.Full text  Abstract

388. Department of Health and Social Care. JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021. 2021 [internet publication].Full text

389. Lacy J, Pavord S, Brown KE. VITT and second doses of Covid-19 vaccine. N Engl J Med. 2022 Jan 6;386(1):95.Full text  Abstract

390. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021. 2021 [internet publication].Full text

391. European Medicines Agency. COVID-19 vaccine safety update: Vaxzevria – AstraZeneca AB. November 11 2021 [internet publication].Full text

392. Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021 Sep 1;4(9):e2125524.Full text  Abstract

393. Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021 Oct;9(10):3546-67.Full text  Abstract

394. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109.Full text  Abstract

395. Krantz MS, Kwah JH, Stone CA Jr, et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021 Nov 1;181(11):1530-3.Full text  Abstract

396. Fazlollahi A, Zahmatyar M, Noori M, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2021 Dec 17:e2318.Full text  Abstract

397. Elboraey MO, Essa EESF. Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Oct;132(4):e139-42.Full text  Abstract

398. Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov;3(11):e743-4.Full text  Abstract

399. Askenase PW. Rare skin reactions after mRNA vaccination, similar to Jones-Mote basophil responses. N Engl J Med. 2021 Oct 28;385(18):1720-1.Full text  Abstract

400. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves' disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021 Sep;31(9):1436-9.Full text  Abstract

401. Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol. 2022 Jan 5 [Epub ahead of print].Full text  Abstract

402. Walter T, Connor S, Stedman C, et al. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. Br J Clin Pharmacol. 2021 Aug 22 [Epub ahead of print].Full text  Abstract

403. Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2021 Dec 27 [Epub ahead of print].Full text  Abstract

404. Patone M, Mei XW, Handunnetthi L, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021 Dec 14 [Epub ahead of print].Full text  Abstract

405. Wu HHL, Kalra PA, Chinnadurai R. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Vaccines (Basel). 2021 Oct 29;9(11):1252.Full text  Abstract

406. Maramattom BV, Philips G, Thomas J, et al. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021 Nov;3(11):e747-9.Full text  Abstract

407. Leone F, Cerasuolo PG, Bosello SL, et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol. 2021 Oct;3(10):e678-80.Full text  Abstract

408. Sessa F, Salerno M, Esposito M, et al. Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med. 2021 Dec 15;10(24):5876.Full text  Abstract

409. UK Health Security Agency. COVID-19 vaccination: a guide on pregnancy and breastfeeding. 2021 [internet publication].Full text

410. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2022 [internet publication].Full text

411. American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric–gynecologic care. 2021 [internet publication].Full text

412. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021 Jun 17;384(24):2273-82.Full text  Abstract

413. UK Health Security Agency. New UKHSA study provides more safety data on COVID-19 vaccines in pregnancy. 2021 [internet publication].Full text

414. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth: eight integrated health care organizations, United States, December 15, 2020 – July 22, 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):26-30.Full text  Abstract

415. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA. 2021 May 18;325(19):2013-4.Full text  Abstract

416. Esteve-Palau E, Gonzalez-Cuevas A, Guerrero ME, et al. Quantification of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with an mRNA vaccine. JAMA Netw Open. 2021 Aug 2;4(8):e2120575.Full text  Abstract

417. Golan Y, Prahl M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pediatr. 2021 Oct 1;175(10):1069-71.Full text  Abstract

418. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 Aug 1;147(8):739-43.Full text  Abstract

419. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years: United States, December 14, 2020 – July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1053-8.Full text  Abstract

420. Dyer O. Covid-19: FDA puts Moderna's paediatric application on hold to investigate side effects. BMJ. 2021 Nov 1;375:n2659.Full text  Abstract

421. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2021 Nov 9 [Epub ahead of print].Full text  Abstract

422. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years: United States, November 3 – December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-60.Full text  Abstract

423. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 Apr 8;384(14):1372-4.Full text  Abstract

424. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021 Mar 27;397(10280):1178-81.Full text  Abstract

425. Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2022 Jan;3(1):e21-31.Full text  Abstract

426. Ossato A, Tessari R, Trabucchi C, et al. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm. 2021 Jul 27 [Epub ahead of print].Full text  Abstract

427. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults: nine states, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-9.Full text  Abstract

428. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2021 Aug 30:102927.Full text  Abstract

429. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Sep;3(9):e627-37.Full text  Abstract

430. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021 Nov;3(11):e789-97.Full text  Abstract

431. Ishay Y, Kenig A, Tsemach-Toren T, et al. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021 Jul 10;99:107970.Full text  Abstract

432. Cabreira V, Abreu P, Soares-Dos-Reis R, et al. Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel). 2021 Jul 11;9(7):773.Full text  Abstract

433. Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021 Sep;3(9):e613-5.Full text  Abstract

434. Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021 Sep;3(9):e617.Full text  Abstract

435. Gagelmann N, Passamonti F, Wolschke C, et al. Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis. Haematologica. 2021 Dec 16 [Epub ahead of print].Full text  Abstract

436. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15.Full text  Abstract

437. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403-16.Full text  Abstract

438. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187-201.Full text  Abstract

439. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Dec 16;385(25):2348-60.Full text  Abstract

440. Hayawi K, Shahriar S, Serhani MA, et al. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines (Basel). 2021 Nov 10;9(11):1305.Full text  Abstract

441. Kow CS, Ramachandram DS, Hasan SS. The effectiveness of mRNA-1273 vaccine against COVID-19 caused by delta variant: a systematic review and meta-analysis. J Med Virol. 2022 Jan 3 [Epub ahead of print].Full text  Abstract

442. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. N Engl J Med. 2022 Jan 5 [Epub ahead of print].Full text  Abstract

443. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 Apr 23;:1-20.Full text  Abstract

444. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Jun;20(6):347-8.Full text  Abstract

445. Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants: a potential risk for mass vaccination? J Infect. 2021 Nov;83(5):607-35.Full text  Abstract

446. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. 2021 [internet publication].Full text

447. European Medicines Agency. EMA starts rolling review of Evusheld (tixagevimab and cilgavimab). 2021 [internet publication].Full text

448. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2022 [internet publication].Full text

449. AstraZeneca. New analyses of two AZD7442 COVID-19 phase III trials in high-risk populations confirm robust efficacy and long-term prevention. 2021 [internet publication].Full text

450. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2021 [internet publication].Full text

451. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19) is suspected or confirmed: interim guidance. 2021 [internet publication].Full text

452. World Health Organization. WHO recommendations on mask use by health workers, in light of the Omicron variant of concern: WHO interim guidelines, 22 December 2021. 2021 [internet publication].Full text

453. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ. 2020 Jun 10;369:m2195.Full text  Abstract

454. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? 2020 [internet publication].Full text

455. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Full text  Abstract

456. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2021 [internet publication].Full text

457. Centers for Disease Control and Prevention. How to protect yourself and others. 2021 [internet publication].Full text

458. Bendavid E, Oh C, Bhattacharya J, et al. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest. 2021 Jan 5:e13484.Full text  Abstract

459. Chu IY, Alam P, Larson H, et al. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J Travel Med. 2020 Nov 9;27(7):taaa192.Full text  Abstract

460. World Health Organization. COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021. 2021 [internet publication].Full text

461. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021 Mar;174(3):335-43.Full text  Abstract

462. Nanda A, Hung I, Kwong A, et al. Efficacy of surgical masks or cloth masks in the prevention of viral transmission: systematic review, meta-analysis, and proposal for future trial. J Evid Based Med. 2021 May;14(2):97-111.Full text  Abstract

463. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;(11):CD006207.Full text  Abstract

464. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Full text  Abstract

465. Chou R, Dana T, Jungbauer R, et al. Update alert 6: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. Ann Intern Med. 2021 Sep;174(9):W68.Full text  Abstract

466. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Full text  Abstract

467. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Full text  Abstract

468. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Full text  Abstract

469. Bakhit M, Krzyzaniak N, Scott AM, et al. Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis. BMJ Open. 2021 Feb 22;11(2):e044364.Full text  Abstract

470. Burns J, Movsisyan A, Stratil JM, et al. Travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020 Oct 5;(10):CD013717.Full text  Abstract

471. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013718.Full text  Abstract

472. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013574.Full text  Abstract

473. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Full text  Abstract

474. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Full text  Abstract

475. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19;10(11):e040402.Full text  Abstract

476. Department of Health and Social Care. Everyone in the United Kingdom with symptoms now eligible for coronavirus tests. 2021 [internet publication].Full text

477. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2021 Feb 23;(2):CD013665.Full text  Abstract

478. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Full text

479. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440-8.Full text  Abstract

480. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Full text

481. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Full text

482. Centers for Disease Control and Prevention. Ten clinical tips on COVID-19 for healthcare providers involved in patient care. 2020 [internet publication].Full text

483. ZOE COVID Symptom Study. What are the new top 5 COVID symptoms? 2021 [internet publication].Full text

484. ZOE COVID Study. Omicron and cold-like symptoms rapidly taking over in London. 2021 [internet publication].Full text

485. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 1;72(3):521-33.Full text  Abstract

486. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Full text  Abstract

487. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021 Apr;27 Suppl 3:710-2.Full text  Abstract

488. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Full text  Abstract

489. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Full text  Abstract

490. Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170.Full text  Abstract

491. Wang Y, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: a rapid review and meta-analysis. Int J Clin Pract. 2021 Nov;75(11):e14867.Full text  Abstract

492. Achan J, Serwanga A, Wanzira H, et al. Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda. Lancet Microbe. 2022 Jan;3(1):e62-71.Full text  Abstract

493. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids: an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;:1-8.Full text  Abstract

494. Mahase E. Covid-19: Children less likely to report fever, persistent cough, or appetite loss, large UK study finds. BMJ. 2021 Feb 10;372:n408.Full text  Abstract

495. Bolia R, Dhanesh Goel A, Badkur M, et al. Gastrointestinal manifestations of pediatric coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr. 2021 May 17;67(2):fmab051.Full text  Abstract

496. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Abstract

497. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Full text  Abstract

498. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Full text  Abstract

499. Rubens JH, Akindele NP, Tschudy MM, et al. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021 Mar 1;372:n385.Full text  Abstract

500. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Full text  Abstract

501. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Full text  Abstract

502. Vasudevan RS, Bin Thani K, Aljawder D, et al. The stethoscope: a potential vector for COVID-19? Eur Heart J. 2020 Sep 21;41(36):3393-5.Full text  Abstract

503. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Full text  Abstract

504. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Full text  Abstract

505. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2021 [internet publication].Full text

506. US Food and Drug Administration. Pulse oximeter accuracy and limitations: FDA safety communication. 2021 [internet publication].Full text

507. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Full text

508. Zhang K, Zhang X, Ding W, et al. The prognostic accuracy of national early warning score 2 on predicting clinical deterioration for patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 9;8:699880.Full text  Abstract

509. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Full text  Abstract

510. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Full text  Abstract

511. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Full text  Abstract

512. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Full text  Abstract

513. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Full text  Abstract

514. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Full text  Abstract

515. Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2021 Dec 20 [Epub ahead of print].Full text  Abstract

516. World Health Organization. WHO information notice for IVD users 2020/05. 2021 [internet publication].Full text

517. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. 2021 [internet publication].Full text

518. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance. 2021 [internet publication].Full text

519. UK Health Security Agency. COVID-19: investigation and initial clinical management of possible cases. 2020 [internet publication].Full text

520. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2021 [internet publication].Full text

521. Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Apr 12;21(9):1233-45.Full text  Abstract

522. Bastos ML, Perlman-Arrow S, Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-10.Full text  Abstract

523. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021 Mar 1;181(3):353-60.Full text  Abstract

524. Cañete MG, Valenzuela IM, Garcés PC, et al. Saliva sample for the massive screening of SARS-CoV-2 infection: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):540-8.Full text  Abstract

525. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel). 2021 Feb 21;11(2):363.Full text  Abstract

526. Atieh MA, Guirguis M, Alsabeeha NHM, et al. The diagnostic accuracy of saliva testing for SARS-CoV-2: a systematic review and meta-analysis. Oral Dis. 2021 Jun 3 [Epub ahead of print].Full text  Abstract

527. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0253007.Full text  Abstract

528. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. 2021 [internet publication].Full text

529. Centers for Disease Control and Prevention. Nucleic acid amplification tests (NAATs). 2021 [internet publication].Full text

530. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. PLoS One. 2021 Jul 20;16(7):e0254559.Full text  Abstract

531. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2021 May;42(5):641-2.Full text  Abstract

532. Koskinen A, Tolvi M, Jauhiainen M, et al. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):672-4.Full text  Abstract

533. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1179-81.Full text  Abstract

534. Knížek Z, Michálek R, Vodicka J, et al. Cribriform plate injury after nasal swab testing for COVID-19. JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):915-7.Full text  Abstract

535. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020 Oct 1 [Epub ahead of print].Full text  Abstract

536. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Full text

537. Jefferson T, Spencer EA, Brassey J, et al. Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review. Clin Infect Dis. 2021 Dec 6;73(11):e3884-99.Full text  Abstract

538. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Full text  Abstract

539. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 Dec 17;71(10):2663-6.Full text  Abstract

540. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Full text  Abstract

541. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Dec;8(12):1167-8.Full text  Abstract

542. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Full text  Abstract

543. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Full text

544. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2021 [internet publication].Full text

545. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Full text

546. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Full text

547. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020 Dec 10;15(12):e0242958.Full text  Abstract

548. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Full text  Abstract

549. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Full text  Abstract

550. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2021 [internet publication].Full text

551. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Full text

552. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Full text  Abstract

553. Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19;71(16):2255-8.Full text  Abstract

554. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Full text  Abstract

555. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. 2021 [internet publication].Full text

556. Government of the United Kingdom. Order coronavirus (COVID-19) rapid lateral flow tests. 2022 [internet publication].Full text

557. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing. 2021 [internet publication].Full text

558. Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. 2021 [internet publication].Full text

559. US Food and Drug Administration. Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2020 [internet publication].Full text

560. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021 Mar 24;(3):CD013705.Full text  Abstract

561. Mistry DA, Wang JY, Moeser ME, et al. A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis. 2021 Aug 18;21(1):828.Full text  Abstract

562. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021 Jul 6;374:n1637.Full text  Abstract

563. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021 Jun 26;69:103455.Full text  Abstract

564. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med. 2021 Aug;18(8):e1003735.Full text  Abstract

565. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Full text

566. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Full text  Abstract

567. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. 2020 [internet publication].Full text

568. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Jul 27;80:229-38.Full text  Abstract

569. Islam N, Ebrahimzadeh S, Salameh JP, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2021 Mar 16;(3):CD013639.Full text  Abstract

570. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Full text

571. Centre for Evidence-Based Medicine; Park JY, Freer R, Stevens R, et al. The accuracy of chest CT in the diagnosis of COVID-19: an umbrella review. 2021 [internet publication].Full text

572. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Full text  Abstract

573. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Full text

574. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-24.Full text  Abstract

575. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Full text  Abstract

576. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Full text  Abstract

577. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-64.Full text  Abstract

578. Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021 Jan 13;75:75-82.Full text  Abstract

579. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Full text  Abstract

580. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Full text  Abstract

581. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Full text  Abstract

582. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Full text  Abstract

583. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Full text  Abstract

584. Wang JG, Mo YF, Su YH, et al. Computed tomography features of COVID-19 in children: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Sep 24;100(38):e22571.Full text  Abstract

585. Ghodsi A, Bijari M, Alamdaran SA, et al. Chest computed tomography findings of COVID-19 in children younger than 1 year: a systematic review. World J Pediatr. 2021 Jun;17(3):234-41.Full text  Abstract

586. Mohamed MFH, Al-Shokri S, Yousaf Z, et al. Frequency of abnormalities detected by point-of-care lung ultrasound in symptomatic COVID-19 patients: systematic review and meta-analysis. Am J Trop Med Hyg. 2020 Aug;103(2):815-21.Full text  Abstract

587. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Full text  Abstract

588. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Full text  Abstract

589. Caroselli C, Blaivas M, Falzetti S. Diagnostic imaging in newborns, children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): is there a realistic alternative to lung high-resolution computed tomography (HRCT) and chest x-rays? A systematic review of the literature. Ultrasound Med Biol. 2021 Nov;47(11):3034-40.Full text  Abstract

590. Pillai K, Hewage S, Harky A. The role of the lung ultrasound in coronavirus disease 2019: a systematic review. J Med Ultrasound. 2020 Oct-Dec;28(4):207-12.Full text  Abstract

591. Song G, Qiao W, Wang X, et al. Association of lung ultrasound score with mortality and severity of COVID-19: a meta-analysis and trial sequential analysis. Int J Infect Dis. 2021 Jul;108:603-9.Full text  Abstract

592. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Full text  Abstract

593. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Full text  Abstract

594. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Full text  Abstract

595. Baba MM, Bitew M, Fokam J, et al. Diagnostic performance of a colorimetric RT-LAMP for the identification of SARS-CoV-2: a multicenter prospective clinical evaluation in sub-Saharan Africa. EClinicalMedicine. 2021 Aug 28;40:101101.Full text  Abstract

596. Subali AD, Wiyono L. Reverse Transcriptase Loop Mediated Isothermal AmplifiCation (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis. Pathog Glob Health. 2021 Jun 4:1-11.Full text  Abstract

597. Udeh R, Advani S, de Guadiana Romualdo LG, et al. Calprotectin, an emerging biomarker of interest in COVID-19: a systematic review and meta-analysis. J Clin Med. 2021 Feb 15;10(4):775.Full text  Abstract

598. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Full text  Abstract

599. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Full text  Abstract

600. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.Full text  Abstract

601. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Full text  Abstract

602. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533-44.Full text  Abstract

603. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Full text  Abstract

604. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Full text  Abstract

605. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Full text  Abstract

606. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Full text  Abstract

607. Santos REA, da Silva MG, do Monte Silva MCB, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol. 2021 Jan 6;42(2):102889.Full text  Abstract

608. Jafar A, Lasso A, Shorr R, et al. Olfactory recovery following infection with COVID-19: a systematic review. PLoS One. 2021 Nov 9;16(11):e0259321.Full text  Abstract

609. Renaud M, Thibault C, Le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021 Jun 1;4(6):e2115352.Full text  Abstract

610. Hariyanto TI, Rizki NA, Kurniawan A. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis. Int Arch Otorhinolaryngol. 2021 Jan;25(1):e170-4.Full text  Abstract

611. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 May;87(5):2186-8.Full text  Abstract

612. Yan Q, Qiu D, Liu X, et al. Prevalence of smell or taste dysfunction among children with COVID-19 infection: a systematic review and meta-analysis. Front Pediatr. 2021 Aug 3;9:686600.Full text  Abstract

613. Mutiawati E, Syahrul S, Fahriani M, et al. Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. F1000Res. 2020 Nov 12;9:1316.Full text  Abstract

614. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Nov;2(11):e655-7.Full text  Abstract

615. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Full text  Abstract

616. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for coronavirus infection? A prospective case-control study from the United States. Gastroenterology. 2020 Sep;159(3):1161-3.Full text  Abstract

617. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Full text  Abstract

618. Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):168-76.Full text  Abstract

619. Shehab M, Alrashed F, Shuaibi S, et al. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Mar;8(1):e000571.Full text  Abstract

620. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Full text  Abstract

621. Shao SC, Lai CC, Chen YH, et al. Prevalence, incidence and mortality of delirium in patients with COVID-19: A systematic review and meta-analysis. Age Ageing. 2021 Sep 11;50(5):1445-53.Full text  Abstract

622. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021 Mar;9(3):239-50.Full text  Abstract

623. Cénat JM, Blais-Rochette C, Kokou-Kpolou CK, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020 Nov 26;295:113599.Full text  Abstract

624. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82.Full text  Abstract

625. Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021 Jan-Mar;16(1):103-12.Full text  Abstract

626. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Full text  Abstract

627. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Oct 1;138(10):1079-86.Full text  Abstract

628. Zhong Y, Wang K, Zhu Y, et al. Ocular manifestations in COVID-19 patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2021 Nov-Dec;44:102191.Full text  Abstract

629. Sen S, Kannan NB, Kumar J, et al. Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. Int Ophthalmol. 2021 Aug 11 [Epub ahead of print].Full text  Abstract

630. Ullah I, Sohail A, Shah MUFA, et al. Central retinal vein occlusion in patients with COVID-19 infection: a systematic review. Ann Med Surg (Lond). 2021 Oct 8:102898.Full text  Abstract

631. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11.Full text  Abstract

632. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Full text  Abstract

633. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Nov;59(11):1358-70.Full text  Abstract

634. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-like lesions (CLL) associated with COVID-19 ("COVID toes"): a systematic review. J Cutan Med Surg. 2021 Nov-Dec;25(6):627-33.Full text  Abstract

635. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021 May;184(5):880-7.Full text

636. Schwartzberg LN, Advani S, Clancy DC, et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021 Jun;1(2):e20.Full text  Abstract

637. Shah S, Akhade K, Ganguly S, et al. Cutaneous manifestations associated with COVID-19 in children: a systematic review. J Family Med Prim Care. 2021 Jan;10(1):93-101.Full text  Abstract

638. Discepolo V, Catzola A, Pierri L, et al. Bilateral chilblain-like lesions of the toes characterized by microvascular remodeling in adolescents during the COVID-19 pandemic. JAMA Netw Open. 2021 Jun 1;4(6):e2111369.Full text  Abstract

639. Erbaş GS, Botsali A, Erden N, et al. COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review. Int J Dermatol. 2022 Jan;61(1):20-32.Full text  Abstract

640. Holcomb ZE, Hussain S, Huang JT, et al. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol. 2021 May 1;157(5):603-5.Full text  Abstract

641. Mashayekhi F, Seirafianpour F, Pour Mohammad A, et al. Severe and life-threatening COVID-19-related mucocutaneous eruptions: a systematic review. Int J Clin Pract. 2021 Aug 19:e14720.Full text  Abstract

642. Bhujel N, Zaheer K, Singh RP. Oral mucosal lesions in patients with COVID-19: a systematic review. Br J Oral Maxillofac Surg. 2021 Nov;59(9):1024-30.Full text  Abstract

643. Creta M, Sagnelli C, Celentano G, et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: a systematic review. J Med Virol. 2021 May;93(5):3133-42.Full text  Abstract

644. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? A systematic review. Prostate Cancer Prostatic Dis. 2021 May 18 [Epub ahead of print].Full text  Abstract

645. US Food and Drug Administration. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2021 [internet publication].Full text

646. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. 2020 [internet publication].Full text

647. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Full text  Abstract

648. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic role of anemia in COVID-19 patients: a meta-analysis. Infect Dis Rep. 2021 Oct 31;13(4):930-7.Full text  Abstract

649. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Full text  Abstract

650. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Full text  Abstract

651. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Full text  Abstract

652. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Full text  Abstract

653. Alemzadeh E, Alemzadeh E, Ziaee M, et al. The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun Inflamm Dis. 2021 Dec;9(4):1219-28.Full text  Abstract

654. Akbar MR, Pranata R, Wibowo A, et al. The prognostic value of hyponatremia for predicting poor outcome in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jun 14;8:666949.Full text  Abstract

655. Lazarus G, Audrey J, Kharisma Wangsaputra V, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020 Dec 9:108561.Full text  Abstract

656. Handayani DR, Juliastuti H, Nawangsih EN, et al. Prognostic value of fasting hyperglycemia in patients with COVID-19: diagnostic test accuracy meta-analysis. Obes Med. 2021 Apr 4:100333.Full text  Abstract

657. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.Full text  Abstract

658. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221-31.Full text  Abstract

659. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Abstract

660. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Full text  Abstract

661. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Full text  Abstract

662. Zinellu A, Paliogiannis P, Carru C, et al. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Adv Med Sci. 2021 Jul 21;66(2):372-80.Full text  Abstract

663. Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M. High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med. 2021 Nov 6 [Epub ahead of print].Full text  Abstract

664. Wungu CDK, Khaerunnisa S, Putri EAC, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis. 2021 Mar 9;105:551-9.Full text  Abstract

665. Yitbarek GY, Walle Ayehu G, Asnakew S, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021 Oct 11;9:20503121211050755.Full text  Abstract

666. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun 14;42(23):2270-9.Full text  Abstract

667. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 Jun;61(3):253-4.Full text  Abstract

668. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Full text  Abstract

669. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Full text  Abstract

670. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Full text  Abstract

671. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Full text  Abstract

672. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2021 Jul 2;67(3):fmaa045.Full text  Abstract

673. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Full text  Abstract

674. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Full text  Abstract

675. Mair MDD, Hussain M, Siddiqui S, et al. A systematic review and meta-analysis comparing the diagnostic accuracy of initial RT-PCR and CT scan in suspected COVID-19 patients. Br J Radiol. 2020 Dec 22:20201039.Full text  Abstract

676. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Full text  Abstract

677. US Food and Drug Administration. Stop using Innova Medical Group SARS-CoV-2 antigen rapid qualitative test: FDA safety communication. 2021 [internet publication].Full text

678. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19. 2020 [internet publication].Full text

679. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. 2020 [internet publication].Full text

680. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Full text

681. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Full text  Abstract

682. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Full text  Abstract

683. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Full text  Abstract

684. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Full text  Abstract

685. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review. Adv Clin Exp Med. 2021 Jan;30(1):109-14.Full text  Abstract

686. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Sep;27(9):1738-41.Full text  Abstract

687. Guan Z, Chen C, Li Y, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. 2021 Dec 10;9:773130.Full text  Abstract

688. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Full text  Abstract

689. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Full text  Abstract

690. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Full text  Abstract

691. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Full text  Abstract

692. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2021 [internet publication].Full text

693. Fistera D, Härtl A, Pabst D, et al. What about the others: differential diagnosis of COVID-19 in a German emergency department. BMC Infect Dis. 2021 Sep 17;21(1):969.Full text  Abstract

694. World Health Organization. Considerations for quarantine of contacts of COVID-19 cases: interim guidance. 2021 [internet publication].Full text

695. UK Health Security Agency. Stay at home: guidance for households with possible or confirmed coronavirus (COVID-19) infection. 2022 [internet publication].Full text

696. UK Health Security Agency. Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person. 2022 [internet publication].Full text

697. Centers for Disease Control and Prevention. COVID-19: quarantine and isolation. 2022 [internet publication].Full text

698. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Full text  Abstract

699. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Full text

700. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Dec 23;27(8):taaa193.Full text  Abstract

701. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2021 May;49(5):597-602.Full text  Abstract

702. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. 2021 [internet publication].Full text

703. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on infection prevention for healthcare personnel caring for patients with suspected or known COVID-19. 2021 [internet publication].Full text

704. American Academy of Pediatrics. COVID-19 testing guidance. 2021 [internet publication].Full text

705. UK Health Security Agency; NHS England; Public Health Wales; Public Health Agency (Northern Ireland). COVID-19: infection prevention and control (IPC). 2021 [internet publication].Full text

706. UK Health Security Agency. COVID-19: guidance for health professionals. 2021 [internet publication].Full text

707. Scottish Intercollegiate Guidelines Network. Assessment of COVID-19 in primary care. 2021 [internet publication].Full text

708. Jin YH, Zhan QY, Peng ZY, et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: an evidence-based clinical practice guideline (updated version). Mil Med Res. 2020 Sep 4;7(1):41.Full text  Abstract

709. Li T. Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect. 2020 Mar;9(1):582-5.Full text  Abstract

710. World Health Organization. Therapeutics and COVID-19: living guideline. 2021 [internet publication].Full text

711. Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Full text  Abstract

712. Rochwerg B, Siemieniuk RA, Lamontagne R, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2021 Dec 6;375:n2936. Abstract

713. Mahase E. Covid-19: is it safe to reduce the self-isolation period? BMJ. 2021 Dec 30;375:n3164.Full text  Abstract

714. Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jun 9:100941.Full text  Abstract

715. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Full text

716. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2021 Apr;26(2):57-64.Full text  Abstract

717. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 Jun 23;323(24):2512-4.Full text  Abstract

718. Medicines and Healthcare products Regulatory Agency. Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19. 2021 [internet publication].Full text

719. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231.Full text  Abstract

720. European Medicines Agency. COVID-19: EMA recommends authorisation of two monoclonal antibody medicines. 2021 [internet publication].Full text

721. Celltrion Healthcare. Celltrion’s COVID-19 treatment candidate receives Korean MFDS conditional marketing authorisation. 2021 [internet publication].Full text

722. Celltrion Healthcare. Celltrion announces positive top-line results from global phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment. 2021 [internet publication].Full text

723. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2021 Dec 22 [Epub ahead of print].Full text  Abstract

724. CDC COVID-19 Response Team. Coronavirus disease 2019 in children: United States, February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-6.Full text  Abstract

725. Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324.Full text  Abstract

726. Kastora S, Kounidas G, Perrott S, et al. Clinical frailty scale as a point of care prognostic indicator of mortality in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100896.Full text  Abstract

727. Cosco TD, Best J, Davis D, et al. What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing. 2021 May 5;50(3):608-16.Full text  Abstract

728. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Full text

729. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021 Mar 1;49(3):e219-34.Full text  Abstract

730. Ponnapa Reddy M, Subramaniam A, Afroz A, et al. Prone positioning of nonintubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care Med. 2021 Oct 1;49(10):e1001-14.Full text  Abstract

731. Chua EX, Zahir SMISM, Ng KT, et al. Effect of prone versus supine position in COVID-19 patients: a systematic review and meta-analysis. J Clin Anesth. 2021 Jun 22;74:110406.Full text  Abstract

732. Beran A, Mhanna M, Srour O, et al. Effect of prone positioning on clinical outcomes of non-intubated subjects with COVID-19: a comparative systematic review and meta-analysis. Respir Care. 2021 Nov 9 [Epub ahead of print].Full text  Abstract

733. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Full text  Abstract

734. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Full text

735. UK Health Security Agency. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Full text

736. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 Jul;50(1):72-81.Full text  Abstract

737. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143-63.Full text  Abstract

738. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2021 [internet publication].Full text

739. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated heparin in hospitalized COVID-19 patients. EClinicalMedicine. 2021 Mar 9:100774.Full text  Abstract

740. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 Jun 12;397(10291):2253-63.Full text  Abstract

741. Kyriakoulis KG, Kollias A, Kyriakoulis IG, et al. Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports. Curr Vasc Pharmacol. 2021 Aug 24 [Epub ahead of print]. Abstract

742. Giossi R, Menichelli D, Pani A, et al. A systematic review and a meta-analysis comparing prophylactic and therapeutic low molecular weight heparins for mortality reduction in 32,688 COVID-19 patients. Front Pharmacol. 2021 Sep 2;12:698008.Full text  Abstract

743. Zhang S, Li Y, Liu G, et al. Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. Thromb J. 2021 Nov 24;19(1):91.Full text  Abstract

744. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021 Dec 1;181(12):1612-20.Full text  Abstract

745. Li P, Zhao W, Kaatz S, et al. Factors associated with risk of postdischarge thrombosis in patients with COVID-19. JAMA Netw Open. 2021 Nov 1;4(11):e2135397.Full text  Abstract

746. Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022 Jan 1;399(10319):50-9.Full text  Abstract

747. Flumignan RL, Tinôco JDS, Pascoal PI, et al. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;(10):CD013739.Full text  Abstract

748. Moonla C, Sosothikul D, Chiasakul T, et al. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999.Full text  Abstract

749. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-31.Full text  Abstract

750. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41.Full text  Abstract

751. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.Full text  Abstract

752. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19: interim WHO Solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497-511.Full text  Abstract

753. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-45.Full text  Abstract

754. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-502.Full text  Abstract

755. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 Mar 18;(3):CD013881.Full text  Abstract

756. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Full text  Abstract

757. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021 Mar 31;372:n858.Full text  Abstract

758. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Aug 10;326(6):499-518.Full text  Abstract

759. Medicines and Healthcare products Regulatory Agency. Neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with COVID-19 infection. 2021 [internet publication].Full text

760. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: a rapid systematic review. Palliat Med. 2021 Jun;35(6):1099-107.Full text  Abstract

761. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Full text  Abstract

762. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 Apr;76(4):537-48.Full text  Abstract

763. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 May 21;382(21):2012-22.Full text  Abstract

764. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Full text  Abstract

765. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Full text  Abstract

766. Chang R, Elhusseiny KM, Yeh YC, et al. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes: a systematic review and meta-analysis. PLoS One. 2021 Feb 11;16(2):e0246318.Full text  Abstract

767. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-61.Full text  Abstract

768. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021 Mar;180(3):689-97.Full text  Abstract

769. Weerakkody S, Arina P, Glenister J, et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2021 Nov 9 [Epub ahead of print].Full text  Abstract

770. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Aug 4;173(3):204-16.Full text  Abstract

771. Ute Muti-Schüenemann GE, Szczeklik W, Solo K, et al. Update alert 3: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2021 Dec 14 [Epub ahead of print].Full text  Abstract

772. Perkins GD, Ji C, Connolly BA, et al; medRxiv. An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 [preprint]. 2021 [internet publication].Full text

773. Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021 Dec 7;326(21):2161-71. Abstract

774. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Full text  Abstract

775. Elsayed HH, Hassaballa AS, Ahmed TA, et al. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252760.Full text  Abstract

776. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Full text  Abstract

777. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Full text  Abstract

778. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102.Full text  Abstract

779. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Jun 9;323(22):2329-30.Full text  Abstract

780. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 May 21;55(5):2001028.Full text  Abstract

781. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Full text  Abstract

782. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management. Ann Am Thorac Soc. 2020 Sep;17(9):1161-3.Full text  Abstract

783. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Full text  Abstract

784. Bos LDJ, Sjoding M, Sinha P, et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir Med. 2021 Dec;9(12):1377-86.Full text  Abstract

785. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Jul;17(7):787-9.Full text  Abstract

786. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-7.Full text  Abstract

787. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Full text  Abstract

788. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Full text  Abstract

789. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021 Nov 12 [Epub ahead of print].Full text  Abstract

790. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11;155(10):990-2.Full text  Abstract

791. Kannapadi NV, Jami M, Premraj L, et al. Neurological complications in COVID-19 patients with ECMO support: a systematic review and meta-analysis. Heart Lung Circ. 2021 Oct 28 [Epub ahead of print].Full text  Abstract

792. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Full text  Abstract

793. Sarfraz A, Sarfraz Z, Razzack AA, et al. Venous thromboembolism, corticosteroids and COVID-19: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621993573.Full text  Abstract

794. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Full text  Abstract

795. American College of Obstetricians and Gynecologists. Novel coronavirus 2019 (COVID-19). 2021 [internet publication].Full text

796. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Jun;20(6):652-3.Full text  Abstract

797. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6. Abstract

798. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2021 [internet publication].Full text

799. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2021 Feb 1;175(2):157-67.Full text  Abstract

800. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Full text

801. Ronchi A, Pietrasanta C, Zavattoni M, et al. Evaluation of rooming-in practice for neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection in Italy. JAMA Pediatr. 2021 Mar 1;175(3):260-6.Full text  Abstract

802. Centers for Disease Control and Prevention. Evaluation and management considerations for neonates at risk for COVID-19. 2020 [internet publication].Full text

803. Centers for Disease Control and Prevention. COVID-19: care for breastfeeding women. 2021 [internet publication].Full text

804. Medicines and Healthcare products Regulatory Agency. Oral COVID-19 antiviral, Paxlovid, approved by UK regulator. 2021 [internet publication].Full text

805. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021 [internet publication].Full text

806. European Medicines Agency. EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel. 2021 [internet publication].Full text

807. Pfizer Inc. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. 2021 [internet publication].Full text

808. Medicines and Healthcare products Regulatory Agency. First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA. 2021 [internet publication].Full text

809. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. 2021 [internet publication].Full text

810. European Medicines Agency. EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19. 2021 [internet publication].Full text

811. Medicines and Healthcare products Regulatory Agency. Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19. 2021 [internet publication].Full text

812. Merck. Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19. 2021 [internet publication].Full text

813. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021 Dec 16 [Epub ahead of print].Full text  Abstract

814. Singh AK, Singh A, Singh R, et al. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021 Oct 30;15(6):102329.Full text  Abstract

815. US Food and Drug Administration. Frequently asked questions on the emergency use authorization of baricitinib for treatment of COVID-19. 2021 [internet publication].Full text

816. European Medicines Agency. EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen. 2021 [internet publication].Full text

817. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.Full text  Abstract

818. Wijaya I, Andhika R, Huang I, et al. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100755.Full text  Abstract

819. Lin Z, Niu J, Xu Y, et al. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2021 Nov 30 [Epub ahead of print].Full text  Abstract

820. Chen CX, Wang JJ, Li H, et al. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021 Sep;35(9):2616-20.Full text  Abstract

821. Patoulias D, Doumas M, Papadopoulos C, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov;40(11):4671-4.Full text  Abstract

822. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021 [internet publication].Full text

823. European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. 2021 [internet publication].Full text

824. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Full text

825. Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021 Oct;3(10):e690-7.Full text  Abstract

826. Barkas F, Ntekouan SF, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 1;60(12):5527-37.Full text  Abstract

827. Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021 Jun;53(2):221-37.Full text  Abstract

828. Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021 May;80(5):550-7.Full text  Abstract

829. Mehta KG, Patel T, Chavda PD, et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open. 2021 Oct;7(3):e001746.Full text  Abstract

830. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021 Dec;9(12):1419-26.Full text  Abstract

831. Humanigen. FDA has declined Humanigen’s emergency use authorization (EUA) request for lenzilumab in hospitalized COVID-19 patients. 2021 [internet publication].Full text

832. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021 Dec 1 [Epub ahead of print].Full text  Abstract

833. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-8.Full text  Abstract

834. US Food and Drug Administration. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. 2021 [internet publication].Full text

835. Medicines and Healthcare products Regulatory Agency. Convalescent plasma in the management of hospitalised patients with COVID-19. 2021 [internet publication].Full text

836. Piechotta V, Iannizzi C, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600.Full text  Abstract

837. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021 Mar 23;325(12):1185-95.Full text  Abstract

838. Gupta T, Kannan S, Kalra B, et al. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. Transfus Med. 2021 Dec;31(6):409-20.Full text  Abstract

839. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-75.Full text  Abstract

840. Wardhani SO, Fajar JK, Wulandari L, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Res. 2021 Feb 3;10:64.Full text  Abstract

841. Kloypan C, Saesong M, Sangsuemoon J, et al. Convalescent plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence. Eur J Clin Invest. 2021 Aug 10:e13663.Full text  Abstract

842. Axfors C, Janiaud P, Schmitt AM, et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021 Nov 20;21(1):1170.Full text  Abstract

843. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 29;397(10289):2049-59.Full text  Abstract

844. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience [preprint]. medRxiv. 2020 Aug 12 [Epub ahead of print].Full text  Abstract

845. Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): a meta-analysis. Int Immunopharmacol. 2021 Jul;96:107732.Full text  Abstract

846. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Full text

847. Wang J, Shi P, Chen D, et al. Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis. Stem Cells Dev. 2021 Oct 1;30(19):947-69. Abstract

848. Li Y, Wei Z, Ma X, et al. Efficacy and safety of mesenchymal stromal cells therapy for COVID-19 infection: a systematic review and meta-analysis. Curr Stem Cell Res Ther. 2021 Dec 6 [Epub ahead of print]. Abstract

849. Mesoblast Limited. Mesoblast update on COVID-19 ARDS trial. 2020 [internet publication].Full text

850. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206.Full text  Abstract

851. ClinicalTrials.gov. Interferon lambda for immediate antiviral therapy at diagnosis in COVID-19 (ILIAD). 2021 [internet publication].Full text

852. Eiger BioPharmaceuticals. Eiger BioPharmaceuticals announces positive results of investigator sponsored randomized controlled trial at University of Toronto with peginterferon lambda in outpatients with mild to moderate COVID-19. 2020 [internet publication].Full text

853. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Full text  Abstract

854. Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021 Jul 28;(7):CD015017.Full text  Abstract

855. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 Jun 21;28(4):e434-60.Full text  Abstract

856. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021 Apr 22;28(3):e299-318.Full text  Abstract

857. Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021 Jun 27;15(4):102186.Full text  Abstract

858. Kow CS, Merchant HA, Mustafa ZU, et al. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Oct;73(5):1473-9.Full text  Abstract

859. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Full text  Abstract

860. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021 Apr 26;373:n949.Full text  Abstract

861. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 Jun 28 [Epub ahead of print].Full text  Abstract

862. Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021 Dec 20;114(10):721-32.Full text  Abstract

863. Hill A, Garratt A, Levi J, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis. 2021 Nov;8(11):ofab358.Full text  Abstract

864. Azeez TA, Lakoh S, Adeleke AA, et al. Chemoprophylaxis against COVID-19 among health-care workers using ivermectin in low- and middle-income countries: a systematic review and meta-analysis. Indian J Pharmacol. 2021 Nov-Dec;53(6):493-8.Full text  Abstract

865. PRINCIPLE Trial Collaborative Group. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. 2021 [internet publication].Full text

866. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19: a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021 Jun 27;100981.Full text  Abstract

867. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 Jul 8;58(1):2003725.Full text  Abstract

868. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688.Full text  Abstract

869. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-51.Full text  Abstract

870. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020 Dec 8;324(22):2292-300.Full text  Abstract

871. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 Feb;8(2):ofab050.Full text  Abstract

872. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Jul;9(7):763-72.Full text  Abstract

873. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Sep 4;398(10303):843-55.Full text  Abstract

874. Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ. 2021 Nov 2;375:e068060.Full text  Abstract

875. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med. 2021 Nov 22 [Epub ahead of print].Full text  Abstract

876. Medicines and Healthcare products Regulatory Agency. COVID-19 therapeutic alert: antimicrobials (azithromycin and doxycycline) not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients. 2021 [internet publication].Full text

877. Mangkuliguna G, Glenardi, Susanto N, et al. Efficacy and safety of azithromycin for the treatment of COVID-19: a systematic review and meta-analysis. Tuberc Respir Dis (Seoul). 2021 Oct;84(4):299-316.Full text  Abstract

878. Ayerbe L, Risco-Risco C, Forgnone I, et al. Azithromycin in patients with COVID-19: a systematic review and meta-analysis. J Antimicrob Chemother. 2021 Nov 17 [Epub ahead of print].Full text  Abstract

879. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-12.Full text  Abstract

880. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021 Sep;9(9):1010-20.Full text  Abstract

881. Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021 Oct;9(10):1130-40.Full text  Abstract

882. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Mar 20;397(10279):1063-74.Full text  Abstract

883. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Full text  Abstract

884. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Full text  Abstract

885. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Full text  Abstract

886. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021 May;9(5):276-92.Full text  Abstract

887. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vitamin D. 2020 [internet publication].Full text

888. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;(5):CD015043.Full text  Abstract

889. Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis. QJM. 2021 May 19;114(3):175-81.Full text  Abstract

890. Pal R, Banerjee M, Bhadada SK, et al. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2021 Jun 24 [Epub ahead of print].Full text  Abstract

891. Szarpak L, Filipiak KJ, Gasecka A, et al. Vitamin D supplementation to treat SARS-CoV-2 positive patients: evidence from meta-analysis. Cardiol J. 2021 Oct 13 [Epub ahead of print].Full text  Abstract

892. Tentolouris N, Samakidou G, Eleftheriadou I, et al. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients: a systematic review, meta-analysis and meta-regression. Diabetes Metab Res Rev. 2021 Dec 29 [Epub ahead of print].Full text  Abstract

893. da Rocha AP, Atallah AN, Aldrighi JM, et al. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. Int J Clin Pract. 2021 Jul 26:e14649.Full text  Abstract

894. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Full text  Abstract

895. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Full text  Abstract

896. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Full text

897. Rawat D, Roy A, Maitra S, et al. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021 Oct 28;15(6):102324.Full text  Abstract

898. Kwak SG, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: a systematic review and meta-analysis. Complement Ther Med. 2021 Dec 22;64:102797.Full text  Abstract

899. Centers for Disease Control and Prevention. Healthcare workers: information on COVID-19. 2021 [internet publication].Full text

900. American Academy of Pediatrics. COVID-19 interim guidance. 2021 [internet publication].Full text

901. World Health Organization. WHO living guideline: drugs to prevent COVID-19 - interim guidance. 2021 [internet publication].Full text

902. BMJ Publishing Group. BMJ's coronavirus (covid-19) hub. 2022 [internet publication].Full text

903. UK Health Security Agency. COVID-19: the green book, chapter 14a. 2022 [internet publication].Full text

904. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021 [internet publication].Full text

905. Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism in COVID-19. 2021 [internet publication].Full text

906. Scottish Intercollegiate Guidelines Network. Managing the long-term effects of COVID-19. 2021 [internet publication].Full text

907. NHS England. Coronavirus specialty guides. 2021 [internet publication].Full text

908. Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048.Full text  Abstract

909. All India Institute Of Medical Sciences; Indian Council of Medical Research. Clinical guidance for management of adult COVID-19 patients. 2021 [internet publication].Full text

910. Japanese Association for Infectious Diseases. COVID-19 infection. 2021 [internet publication].Full text

911. Department of Health Australia. Coronavirus disease 2019 (COVID-19). 2021 [internet publication].Full text

912. First Affiliated Hospital, Zhejiang University School of Medicine. Handbook of COVID-19 prevention and treatment. 2020 [internet publication].Full text

913. National Health Commission of the People's Republic of China; National Administration of Traditional Chinese Medicine of the People's Republic of China. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl). 2020 May 5;133(9):1087-95.Full text  Abstract

914. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Full text  Abstract

915. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-63.Full text  Abstract

916. Dmytriw AA, Chibbar R, Chen PPY, et al. Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. Expert Rev Respir Med. 2021 Oct;15(10):1347-54.Full text  Abstract

917. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1209-16.Full text  Abstract

918. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263.Full text  Abstract

919. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Full text  Abstract

920. Smith C, Odd D, Harwood R, et al; medRxiv. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data [preprint]. 2021 [internet publication].Full text

921. Qian Z, Lu S, Luo X, et al. Mortality and clinical interventions in critically ill patient with coronavirus disease 2019: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 23;8:635560.Full text  Abstract

922. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):773-85.Full text  Abstract

923. Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax. 2021 Nov 24 [Epub ahead of print].Full text  Abstract

924. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern Med. 2021 Apr 1;181(4):471-8.Full text  Abstract

925. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021 Mar 1;4(3):e210417.Full text  Abstract

926. Finelli L, Gupta V, Petigara T, et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021 Apr 1;4(4):e216556.Full text  Abstract

927. Anesi GL, Jablonski J, Harhay MO, et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med. 2021 May;174(5):613-21.Full text  Abstract

928. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 Mar 26:e13554.Full text  Abstract

929. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: an overview [preprint]. 2021 [internet publication].Full text

930. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Full text  Abstract

931. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological updates. 2022 [internet publication].Full text

932. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, et al. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021 Jun;62(2):E311-20.Full text  Abstract

933. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Full text  Abstract

934. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Full text  Abstract

935. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Full text  Abstract

936. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Full text  Abstract

937. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Full text  Abstract

938. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Full text

939. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Full text  Abstract

940. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Full text

941. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Full text

942. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-6.Full text  Abstract

943. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Full text  Abstract

944. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461.Full text  Abstract

945. Zhang L, Hou J, Ma FZ, et al. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch Virol. 2021 Aug;166(8):2071-87.Full text  Abstract

946. Dumitrascu F, Branje KE, Hladkowicz ES, et al. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021 Sep;69(9):2419-29.Full text  Abstract

947. Bellou V, Tzoulaki I, van Smeden M, et al. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J. 2021 Jun 25 [Epub ahead of print].Full text  Abstract

948. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Full text  Abstract

949. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.Full text  Abstract

950. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Full text  Abstract

951. Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Nov;41:101155.Full text  Abstract

952. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients: a systematic review and meta-analysis. Am J Emerg Med. 2022 Jan;51:267-79.Full text  Abstract

953. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020 Dec 3;383(23):2291-3.Full text  Abstract

954. Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 Oct;21(10):1373-82.Full text  Abstract

955. UK Health Security Agency. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections. 2021 [internet publication].Full text

956. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Full text  Abstract

957. Azam M, Sulistiana R, Ratnawati M, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692.Full text  Abstract

958. SeyedAlinaghi S, Oliaei S, Kianzad S, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic ‎review of current evidence. World J Virol. 2020 Dec 15;9(5):79-90.Full text  Abstract

959. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2021 Mar;93(3):1599-604.Full text  Abstract

960. Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021 Jan 30;64:103230.Full text  Abstract

961. Mao YJ, Wang WW, Ma J, et al. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021 Dec 13 [Epub ahead of print].Full text  Abstract

962. Public Health England. New national surveillance of possible COVID-19 reinfection, published by PHE. 2021 [internet publication].Full text

963. Wang J, Kaperak C, Sato T, et al. COVID-19 reinfection: a rapid systematic review of case reports and case series. J Investig Med. 2021 Aug;69(6):1253-5.Full text  Abstract

964. Zucman N, Uhel F, Descamps D, et al. Severe reinfection with South African severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant 501Y.V2. Clin Infect Dis. 2021 Nov 16;73(10):1945-6.Full text  Abstract

965. Resende PC, Bezerra JF, de Vasconcelos RHT, et al. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. 2021 [internet publication].Full text

966. Naveca F, da Costa C, Nascimento V, et al. SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil. 2021 [internet publication].Full text

967. Nonaka CKV, Franco MM, Gräf T, et al. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis. 2021 Feb 19;27(5).Full text  Abstract

968. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Oct 6;324(13):1279-81.Full text  Abstract

969. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection? Rapid, living practice points from the American College of Physicians (version 1). Ann Intern Med. 2021 Jun;174(6):828-35.Full text  Abstract

970. World Health Organization. COVID-19 natural immunity: scientific brief. 2021 [internet publication].Full text

971. Savage HR, Santos VS, Edwards T, et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551.Full text  Abstract

972. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021 Jun;174(6):811-21.Full text  Abstract

973. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jun 1;175(6):594-600.Full text  Abstract

974. Foley MK, Searle SD, Toloue A, et al. Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study. EClinicalMedicine. 2021 Jun 27:100975.Full text  Abstract

975. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-4.Full text  Abstract

976. Alfego D, Sullivan A, Poirier B, et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021 May 24:100902.Full text  Abstract

977. Egbert ER, Xiao S, Colantuoni E, et al. Durability of spike immunoglobin G antibodies to SARS-CoV-2 among health care workers with prior infection. JAMA Netw Open. 2021 Aug 2;4(8):e2123256.Full text  Abstract

978. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. 2020 [internet publication].Full text

979. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063.Full text  Abstract

980. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532.Full text  Abstract

981. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021 Jul 20;2(7):100355.Full text  Abstract

982. Redd AD, Nardin A, Kared H, et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect Dis. 2021 Jul;8(7):ofab143.Full text  Abstract

983. Petráš M. Highly effective naturally acquired protection against COVID-19 persists for at least 1 year: a meta-analysis. J Am Med Dir Assoc. 2021 Nov;22(11):2263-5.Full text  Abstract

984. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021 Apr 17;397(10283):1459-69.Full text  Abstract

985. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204-12.Full text  Abstract

986. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 Oct 1;181(10):1407-8.Full text  Abstract

987. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Full text  Abstract

988. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Dec 11;370(6522):1339-43.Full text  Abstract

989. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021 Oct;21(10):1352-4.Full text  Abstract

990. Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021 Oct 28;13(10):e19102.Full text  Abstract

991. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Full text  Abstract

992. Gendron N, Dragon-Durey MA, Chocron R, et al. Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality. Arthritis Rheumatol. 2021 Nov;73(11):1976-85.Full text  Abstract

993. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Oct;76(10):970-9.Full text  Abstract

994. Zaffanello M, Piacentini G, Nosetti L, et al. Thrombotic risk in children with COVID-19 infection: a systematic review of the literature. Thromb Res. 2021 Jul 16;205:92-8.Full text  Abstract

995. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Full text

996. Cui LY, Cheng WW, Mou ZW, et al. Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis. Int J Infect Dis. 2021 Aug 18;111:154-63.Full text  Abstract

997. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Full text  Abstract

998. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Full text  Abstract

999. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73.Full text  Abstract

1000. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020 Aug 25;324(8):799-801.Full text  Abstract

1001. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Full text  Abstract

1002. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Full text  Abstract

1003. Changal K, Veria S, Mack S, et al. Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis. BMC Cardiovasc Disord. 2021 Dec 31;21(1):626.Full text  Abstract

1004. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Full text  Abstract

1005. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Full text  Abstract

1006. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Full text  Abstract

1007. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Full text  Abstract

1008. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Full text  Abstract

1009. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Jul 1;5(7):831-40.Full text  Abstract

1010. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Full text  Abstract

1011. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Full text  Abstract

1012. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Full text  Abstract

1013. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Full text  Abstract

1014. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and outcomes of acute kidney injury in COVID-19: a systematic review. Blood Purif. 2021 Jun 15:1-14.Full text  Abstract

1015. Cai X, Wu G, Zhang J, et al. Risk factors for acute kidney injury in adult patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Dec 6;8:719472.Full text  Abstract

1016. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021 [internet publication].Full text

1017. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. 2021 [internet publication].Full text

1018. Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021 Sep;18(9):e1003773.Full text  Abstract

1019. Wildwing T, Holt N. The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. Ther Adv Chronic Dis. 2021 Jan 28;12:2040622320976979.Full text  Abstract

1020. Matta J, Wiernik E, Robineau O, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2021 Nov 8 [Epub ahead of print].Full text  Abstract

1021. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID: a systematic review. Int J Clin Pract. 2021 Oct;75(10):e14357.Full text  Abstract

1022. Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100899.Full text  Abstract

1023. Aminian A, Bena J, Pantalone KM, et al. Association of obesity with postacute sequelae of COVID-19). Diabetes Obes Metab. 2021 Sep;23(9):2183-8.Full text  Abstract

1024. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021 Oct;92:55-70.Full text  Abstract

1025. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021 Oct 1;4(10):e2128568.Full text  Abstract

1026. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 Jul;9(7):747-54.Full text  Abstract

1027. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-58.Full text  Abstract

1028. Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 Apr 7Full text  Abstract

1029. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122.Full text  Abstract

1030. Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5 to 6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020 Dec 3;76(4):405-7.Full text  Abstract

1031. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021 Mar;110(3):914-21.Full text  Abstract

1032. Radtke T, Ulyte A, Puhan MA, et al. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. 2021 Jul 15;326(9):869-71.Full text  Abstract

1033. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Full text  Abstract

1034. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.Full text  Abstract

1035. Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021 Sep 1;4(9):e2127403.Full text  Abstract

1036. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021 Apr;174(4):576-8.Full text  Abstract

1037. So M, Kabata H, Fukunaga K, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021 Mar 22;21(1):97.Full text  Abstract

1038. Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021 Apr;76(4):396-8.Full text  Abstract

1039. American Academy of Physical Medicine and Rehabilitation. Multidisciplinary quality improvement initiative. 2021 [internet publication].Full text

1040. Li G, Yang Y, Gao D, et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285-96.Full text  Abstract

1041. Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021 May 19;11(1):10599.Full text  Abstract

1042. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Full text  Abstract

1043. Sodeifian F, Seyedalhosseini ZS, Kian N, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021 Sep 20;8:731436.Full text  Abstract

1044. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Full text  Abstract

1045. Guerrero JI, Barragán LA, Martínez JD, et al. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis. 2021 Jun 2;21(1):515.Full text  Abstract

1046. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020 Dec;41(12):3437-70.Full text  Abstract

1047. Sullivan BN, Fischer T. Age-associated neurological complications of COVID-19: a systematic review and meta-analysis. Front Aging Neurosci. 2021 Aug 2;13:653694.Full text  Abstract

1048. Chua TH, Xu Z, King NKK. Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020 Oct 19:1-20. Abstract

1049. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. 2020 Nov 1;106349.Full text  Abstract

1050. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug;25:100484.Full text  Abstract

1051. LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021 May 1;78(5):536-47.Full text  Abstract

1052. Lu Y, Zhao JJ, Ye MF, et al. The relationship between COVID-19's severity and ischemic stroke: a systematic review and meta-analysis. Neurol Sci. 2021 Jul;42(7):2645-51.Full text  Abstract

1053. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Full text  Abstract

1054. Nannoni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke. 2021 Feb;16(2):137-49.Full text  Abstract

1055. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Full text  Abstract

1056. Tu TM, Seet CYH, Koh JS, et al. Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men. JAMA Netw Open. 2021 Apr 1;4(4):e217498.Full text  Abstract

1057. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Sep;51(9):e254-8.Full text  Abstract

1058. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Full text  Abstract

1059. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3517-29.Full text  Abstract

1060. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-70.Full text  Abstract

1061. Siow I, Lee KS, Zhang JJY, et al. Encephalitis as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol. 2021 Oct;28(10):3491-502.Full text  Abstract

1062. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Full text  Abstract

1063. Khan DSA, Hamid LR, Ali A, et al. Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021 Dec 1;21(1):801.Full text  Abstract

1064. Sun S, Savitz DA, Wellenius GA. Changes in adverse pregnancy outcomes associated with the COVID-19 pandemic in the United States. JAMA Netw Open. 2021 Oct 1;4(10):e2129560.Full text  Abstract

1065. Huntley BJF, Mulder IA, Di Mascio D, et al. Adverse pregnancy outcomes among individuals with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review and meta-analysis. Obstet Gynecol. 2021 Apr 1;137(4):585-96.Full text  Abstract

1066. Stowe J, Smith H, Thurland K, et al. Stillbirths during the COVID-19 pandemic in England, April-June 2020. JAMA. 2021 Jan 5;325(1):86-7.Full text  Abstract

1067. DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization: United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-5.Full text  Abstract

1068. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2021 Jul 2;67(3):fmaa059.Full text  Abstract

1069. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021 Dec 1;49(12):2042-57.Full text  Abstract

1070. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Full text  Abstract

1071. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021 Feb 17;201:23-9.Full text  Abstract

1072. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021 Mar;16(2):309-12.Full text  Abstract

1073. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Full text  Abstract

1074. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Full text  Abstract

1075. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Full text  Abstract

1076. Jain S, Khanna P, Sarkar S. Comparative evaluation of ventilator-associated pneumonia in critically ill COVID-19 and patients infected with other corona viruses: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2021 Sep 28 [Epub ahead of print].Full text  Abstract

1077. Que Y, Hu C, Wan K, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2021 Feb 22;1-14.Full text  Abstract

1078. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr. 2020 Aug 5;226:45-54.Full text  Abstract

1079. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [internet publication].Full text

1080. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 [internet publication].Full text

1081. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021 May;56(5):837-48.Full text  Abstract

1082. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May;5(5):323-31.Full text  Abstract

1083. Kappanayil M, Balan S, Alawani S, et al. Multisystem inflammatory syndrome in a neonate, temporally associated with prenatal exposure to SARS-CoV-2: a case report. Lancet Child Adolesc Health. 2021 Apr;5(4):304-8.Full text  Abstract

1084. Divekar AA, Patamasucon P, Benjamin JS. Presumptive neonatal multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Am J Perinatol. 2021 May;38(6):632-6. Abstract

1085. Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F, et al. Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021 Mar 22:100764.Full text  Abstract

1086. Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2021 Jan;102:319-26.Full text  Abstract

1087. Davies P, du Pré P, Lillie J, et al. One-year outcomes of critical care patients post-COVID-19 multisystem inflammatory syndrome in children. JAMA Pediatr. 2021 Dec 1;175(12):1281-3.Full text  Abstract

1088. Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021 Jul;5(7):473-82.Full text  Abstract

1089. Bilotta C, Perrone G, Adelfio V, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021 Nov 29;12:729251.Full text  Abstract

1090. Waqar U, Ahmed S, Gardezi SMHA, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: a systematic review. Clin Appl Thromb Hemost. Jan-Dec 2021 Jan-Dec;27:10760296211068487.Full text  Abstract

1091. Andrews NJ, Stowe J, Ramsay ME, et al. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Health Eur. 2022 Feb;13:100260.Full text  Abstract

1092. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021 Oct 28;385(18):1680-9.Full text  Abstract

1093. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO global advisory committee on vaccine safety on AstraZeneca COVID-19 vaccine. 2021 [internet publication].Full text

1094. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021 [internet publication].Full text

1095. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021 Nov 23;97(21):e2136-47. Abstract

1096. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: a systematic review. J Neurol Sci. 2021 Aug 3;428:117607.Full text  Abstract

1097. Salih F, Schönborn L, Kohler S, et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med. 2021 Sep 15 [Epub ahead of print].Full text  Abstract

1098. British Society for Haematology. Guidance from the expert haematology panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021 [internet publication].Full text

1099. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). 2021 [internet publication].Full text

1100. The Royal College of Emergency Medicine. Management of patients presenting to the emergency department/acute medicine with symptoms of Covid-19 vaccine induced thrombosis and thrombocytopenia (VITT). 2021 [internet publication].Full text

1101. Furie KL, Cushman M, Elkind MSV, et al; American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021 Jul;52(7):2478-82.Full text  Abstract

1102. International Society on Thrombosis and Haemostasis. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT). 2021 [internet publication].Full text

1103. Hwang J, Park SH, Lee SW, et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Oct 14;42(39):4053-63.Full text  Abstract

1104. Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021 Sep;64(9):993-1001.Full text  Abstract

1105. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Full text  Abstract

1106. Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021 Dec;186(6):739-54.Full text  Abstract

1107. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis – Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1.Full text  Abstract

1108. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021 Dec;64(12):1452-9.Full text  Abstract

1109. Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15(4):102146.Full text  Abstract

1110. Indian Council of Medical Research. Evidence based advisory in the time of COVID-19 (screening, diagnosis and management of mucormycosis). 2021 [internet publication].Full text

1111. Arora N, Gudipati A, Kundu R, et al. Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis. Lancet Infect Dis. 2021 Nov;21(11):1611.Full text  Abstract

1112. Kumar A. Mucormycosis in COVID-19 recovered patients. J Med Virol. 2021 Dec 14 [Epub ahead of print].Full text  Abstract

1113. Pruthi H, Muthu V, Bhujade H, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia. 2021 Dec 22 [Epub ahead of print].Full text  Abstract

1114. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA): from immunology to treatment. J Fungi (Basel). 2020 Jun 24;6(2):91.Full text  Abstract

1115. Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit: Florida, July – August 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):56-7.Full text  Abstract

1116. Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021 Nov 26 [Epub ahead of print].Full text  Abstract

1117. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Full text  Abstract

1118. Mutneja HR, Bhurwal A, Arora S, et al. Acute pancreatitis in patients with COVID-19 is more severe and lethal: a systematic review and meta-analysis. Scand J Gastroenterol. 2021 Dec;56(12):1467-72. Abstract

1119. Yang F, Huang Y, Li T, et al. Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis. Gut. 2021 Oct 20 [Epub ahead of print].Full text  Abstract

1120. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2021 Feb;70(2):440-1.Full text  Abstract

1121. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Full text  Abstract

1122. Aemaz Ur Rehman M, Farooq H, Ali MM, et al. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021 Apr 29:1-13.Full text  Abstract

1123. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24;324(18):1899-901.Full text  Abstract

1124. Ojha V, Mani A, Mukherjee A, et al. Mesenteric ischemia in patients with COVID-19: an updated systematic review of abdominal CT findings in 75 patients. Abdom Radiol (NY). 2021 Nov 10;1-38.Full text  Abstract

1125. Keshavarz P, Rafiee F, Kavandi H, et al. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin Imaging. 2020 Dec 8;73:86-95.Full text  Abstract

1126. Patel S, Parikh C, Verma D, et al. Bowel ischemia in COVID-19: a systematic review. Int J Clin Pract. 2021 Oct 4:e14930.Full text  Abstract

1127. Marasco G, Maida M, Morreale GC, et al. Gastrointestinal bleeding in COVID-19 patients: a systematic review with meta-analysis. Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975.Full text  Abstract

1128. Chen J, Hang Y. Characteristics, risk factors and outcomes of gastrointestinal hemorrhage in COVID-19 patients: a meta-analysis. Pak J Med Sci. 2021 Sep-Oct;37(5):1524-31.Full text  Abstract

1129. Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2021 Dec 20 [Epub ahead of print].Full text  Abstract

1130. Raschke RA, Agarwal S, Rangan P, et al. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021 Apr 13;325(14):1469-70.Full text  Abstract

1131. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-16.Full text  Abstract

1132. Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021 Apr;76(4):402-4.Full text  Abstract

1133. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021 Jul-Aug;27(4):328-37.Full text  Abstract

1134. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Sep 10;56(3):2002113.Full text  Abstract

1135. Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020 May 1;48(8):e657-65.Full text  Abstract

1136. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020 Sep 12;71(6):1393-99.Full text  Abstract

1137. van Klaveren D, Rekkas A, Alsma J, et al. COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19. BMJ Open. 2021 Sep 16;11(9):e051468.Full text  Abstract

1138. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 Aug 1;180(8):1081-9.Full text  Abstract

1139. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open. 2020 Sep 25;10(9):e040729.Full text  Abstract

1140. Berenguer J, Borobia AM, Ryan P, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021 Sep;76(9):920-9.Full text  Abstract

1141. Department of Health and Social Care. New technology to help identify those at high risk from COVID-19. 2021 [internet publication].Full text

1142. Wongvibulsin S, Garibaldi BT, Antar AAR, et al. Development of severe COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Intern Med. 2021 Jun;174(6):777-85.Full text  Abstract

1143. Chua F, Vancheeswaran R, Draper A, et al. Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax. 2021 Jul;76(7):696-703.Full text  Abstract

1144. Yadaw AS, Li YC, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health. 2020 Oct;2(10):e516-25.Full text  Abstract

1145. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020 Sep 9;370:m3339.Full text  Abstract

1146. Knight SR, Gupta RK, Ho A, et al. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO clinical characterisation protocol. Thorax. 2021 Nov 22 [Epub ahead of print].Full text  Abstract

1147. Corrao G, Rea F, Carle F, et al. Stratification of the risk of developing severe or lethal Covid-19 using a new score from a large Italian population: a population-based cohort study. BMJ Open. 2021 Nov 18;11(11):e053281.Full text  Abstract

1148. Banerjee A, Pasea L, Manohar S, et al. 'What is the risk to me from COVID-19?': public involvement in providing mortality risk information for people with 'high-risk' conditions for COVID-19 (OurRisk.CoV). Clin Med (Lond). 2021 Nov;21(6):e620-8.Full text  Abstract

1149. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): COVID-19 and animals. 2021 [internet publication].Full text

1150. Salman D, Vishnubala D, Le Feuvre P, et al. Returning to physical activity after covid-19. BMJ. 2021 Jan 8;372:m4721.Full text  Abstract

1151. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 Sep 1;6(9):1078-87.Full text  Abstract

Use of this content is subject to our disclaimer